title: [Hypertension and palmar plantar erythroderma. Management of adverse events of angiogenetic inhibitors in the treatment of renal cell carcinoma].
abstract: The introduction of angiogenesis inhibitors has altered the systemic therapy of metastatic renal cell carcinoma. Being a"permanent" medication, the management of side effects has special importance, for adverse events may limit therapy. Hypertension (up to 34% of cases) and palmar plantar erythroderma (6-30% of cases) are common side effects.Blood pressure should be monitored during therapy, and arterial hypertension should be treated with a standard medication. If a hypertensive emergency still occurs, a dose reduction or discontinuation of treatment might be indicated.Prophylaxis may prevent or extenuate palmar plantar erythroderma in many cases, enabling regular chemotherapy as planned. In cases with severe clinical symptoms a reduction or interruption of the dose will be necessary. In most cases local therapy is sufficient.
authors.affiliation: Abteilung für Urologie, Kinderurologie und Uro-Onkologie, St. Josef-Hospital, Hospitalstrasse 45, Troisdorf, Germany. norbert.rolfes@josef-hospital.de
authors.forename: N
authors.initials: N
authors.lastname: Rolfes
authors.forename: G
authors.initials: G
authors.lastname: Lümmen
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000150:complications / Q000188:drug therapy*; D003873:Dermatitis, Exfoliative / Q000139:chemically induced* / Q000517:prevention & control*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000139:chemically induced* / Q000517:prevention & control*; D007680:Kidney Neoplasms / Q000150:complications / Q000188:drug therapy*; D008297:Male
chemical_list: D020533:Angiogenesis Inhibitors